Request Demo
Last update 14 Jun 2025
XmAb-2513
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms XMAB 2513, XMAB2513 |
Target |
Action inhibitors |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with XmAb-2513NCT00606645
A Phase 1 Study of Every Other Week XmAb®2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
100 Clinical Results associated with XmAb-2513
Login to view more data
100 Translational Medicine associated with XmAb-2513
Login to view more data
100 Patents (Medical) associated with XmAb-2513
Login to view more data
1
Literatures (Medical) associated with XmAb-251301 Mar 2015British journal of haematologyQ2 · MEDICINE
A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma
Q2 · MEDICINE
Letter
Author: Younes, Anas ; Kumar, Anita ; Fung, Henry C. ; Smith, Mitchell R. ; Blum, Kristie A. ; Foster, Paul A.
This article describes the phase 1 dose-escalation study of XmAb2513 in patients with relapsed or refractory Hodgkin lymphoma.
100 Deals associated with XmAb-2513
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaplastic Large-Cell Lymphoma | Phase 1 | United States | 01 Dec 2007 | |
| Hodgkin's Lymphoma | Phase 1 | United States | 01 Dec 2007 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | Hodgkin's Lymphoma CD30 Positive | 23 | xyhresfvkh(zaixfkhqwl) = hxyrrigvte dnzfvamjus (luoubdrhys ) View more | Negative | 01 Oct 2014 | ||
Phase 1 | 13 | jkzabmbbkl(dhmbnnnryr) = wgwmvurflh jehyvjbbxi (nzjcharpyb ) | - | 20 May 2009 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free